SCHEMBL4231050

SCHEMBL4231050

O=C(O)/C=C/c1cnc(Nc2ccccc2NC(=O)C2CCCCC2)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM4 Q14833 1/20 0.44
▸ MAPK3 P27361 2/20 0.43
▸ CETP P11597 1/20 0.42
▸ HDAC3 O15379 1/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ ACVRL1 P37023 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ CYP2C19 P33261 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ EGFR P00533 1/20 0.40
▸ ROS1 P08922 1/20 0.40
▸ ALK Q9UM73 1/20 0.40
▸ RAB9A P51151 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4231057 1.00 GRM4 (0.44) GRM4MAPK3CETPHDAC3HDAC1
Hydrochloric Acid SCHEMBL4225759 0.90 MAPK3 (0.45) GRM4MAPK3CETPHDAC3HDAC1
Hydrochloric Acid SCHEMBL4225752 0.90 MAPK3 (0.45) GRM4MAPK3CETPHDAC3HDAC1
SCHEMBL4226693 0.88 GRM4 (0.47) GRM4MAPK3CETPHDAC3HDAC1
SCHEMBL4222885 0.85 EGFR (0.50) GRM4SMN1; SMN2HPGDEGFRLMNA
SCHEMBL4222879 0.85 EGFR (0.50) GRM4SMN1; SMN2HPGDEGFRLMNA
SCHEMBL4232075 0.82 CCNA2 (0.39) GRM4MAPK3CETPHDAC3HDAC1
SCHEMBL4232071 0.82 CCNA2 (0.39) GRM4MAPK3CETPHDAC3HDAC1
SCHEMBL4217504 0.82 GRM4 (0.47) GRM4MAPK3CETPHDAC3HDAC1
SCHEMBL4867871 0.78 SIRT2 (0.54) CETPHDAC3HDAC1HDAC2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7557127-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2009-07-07 — — US disclosed
US-20090054464-A1 HDAC INHIBITOR ASTELLAS PHARMA INC. (JP) 2009-02-26 — — US disclosed
US-7465731-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2008-12-16 — — US disclosed
US-20060052599-A1 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2006-03-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052599-A1 HDAC inhibitor HDAC1, HDAC2, HDAC11 GRM4 1272/4885MAPK3 2440/4885CETP 4640/4885
US-20090054464-A1 HDAC INHIBITOR HDAC1, HDAC2, HDAC8 GRM4 1071/4885MAPK3 2911/4885CETP 4739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback